Companies TRIMTECH Therapeutics

Defeating CNS and inflammatory disorders by selectively destroying disease-causing protein aggregates

Spotlight

TRIMTECH Therapeutics is creating a differentiated portfolio of potent, highly specific degraders, known as TRIMTACs™ and TRIMGLUEs™, that selectively target the removal of toxic proteins for the treatment of intractable CNS and inflammatory disorder. The approach is based on pioneering research that elucidated the function and mechanism of action of TRIM21, an underexploited but widely expressed ubiquitin ligase, that can be directed to treat protein aggregation disorders and bring therapeutic benefits.

Cambridge Innovation Capital is a leading Series A investor in the Cambridge ecosystem.

We were born out of a unique relationship with the University of Cambridge and we maintain privileged access to its most inspiring ideas and people in life sciences and deep tech.

Discover more

Insights

Read More